Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882


Delayed Quote. Delayed London Stock Exchange - 09/24 11:39:22 am
1388 GBX   -1.84%
02:12pGLAXOSMITHKLINE ( '') (FORM 6 K : GlaxoSmithKline plc (the 'Company') (Form 6-K)
11:21aEuropean ADRs Move Lower in Friday Trading
06:36aGLAXOSMITHKLINE : UBS sticks Neutral
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GlaxoSmithKline plc : Funding boost for GSK’s open innovation research into diseases affecting the developing world

05/03/2013 | 05:46am EDT

Issued: Friday 3 May 2013, London UK

GlaxoSmithKline plc (GSK) today announced a funding injection of up to £5m from the Wellcome Trust to support its open approach to discovering and developing urgently needed new treatments for diseases of the developing world. 

The funding will move early-stage research to the next level, to find new medicines for diseases such as TB, malaria, Leishmaniasis and sleeping sickness. Scientists from around the world will work in collaboration with GSK drug discovery experts at its facility in Tres Cantos, Madrid - where GSK's work researching diseases of the developing world is focused - with the overarching goal of developing two high-quality experimental drugs over the next five years.

GSK has been committed to an open approach to discovering new treatments for diseases of the developing world since 2010, when it created its Open Lab. Here, external researchers can work on their early stage research alongside GSK scientists at a dedicated facility at Tres Cantos, Madrid, benefiting from GSK facilities, resources and knowledge to help them advance their own research projects. Diseases of the developing world affect millions of people and yet R&D is struggling, due to the complexity of the science and low return on investment. To help address this, GSK's Tres Cantos facility is intended to be an engine room of scientific innovation, stimulating more R&D into diseases that affect the world's poorest people.   Based on the belief that transparency, openness and collaboration are key to igniting research in to these diseases, the Open Lab has, since its establishment, hosted 27 external researchers, who have worked alongside and been supported by GSK scientists on early-stage projects to identify compounds that are active against these diseases.

The £5m Wellcome Trust funding announced today will be used to take this open approach a significant step further, tackling the next phase of drug development with the aim of turning promising active compounds into high quality experimental drugs. The funding will provide the opportunity to progress the most promising projects underway by independent scientists at the Open Lab and from GSK's own research portfolio. Innovative research that has come about using the GSK malaria and TB compound collections - which have been made freely available and publically accessible by GSK - also have the potential to benefit from the Wellcome Trust funding.

Dr Nick Cammack, Head of GSK's Tres Cantos Medicines Development Campus, which houses the Open Lab  said: "This support highlights a growing recognition that collaborative and open research is the key to tackling these devastating diseases. Since adopting an open approach to discovering new medicines for developing world diseases, we've hosted some of the world's brightest academic scientists at Tres Cantos. The fusion of their academic excellence with GSK expertise has yielded some really exciting research projects. This tremendous show of support from the Wellcome Trust means we now have the potential to start driving these projects further towards finding new medicines."

Dr Richard Seabrook, Head of Business Development at the Wellcome Trust, said: "Academic researchers are making incredible progress in our understanding of neglected diseases yet we've still got a bottle neck when it comes to the development of new drugs. Taking a more collaborative approach, as GSK have through their open lab, will see these advances reap the full benefit of the industry's commercial expertise to give us the best chance of securing new treatments for these devastating diseases."

More about GSK's Open Lab

The majority of the early-stage research collaborations currently ongoing at GSK's Open Lab are funded by the Tres Cantos Open Lab Foundation - an independent charity established by GSK in 2010 with £5m seed funding. In 2012 GSK doubled this funding to a total of £10m and it is hoped that with this, and other donations, a sustainable flow of around 10 high quality early stage drug discovery projects will be maintained at the Open Lab in the coming years.

At present there are 12 active projects in the GSK Open Lab portfolio, investigating new treatments for diseases of the developing world including malaria and TB, as well as some of the more traditionally "neglected" diseases. For example, a researcher at NYU School of Medicine last year secured funding to carry out research in to new treatments for Chagas disease, using the Open Lab's specialist screening facilities to identify specific compounds that inhibit the infection. The two medicines currently available to treat this disease are active only during the early stages of infection and have unpleasant side effects, so efforts such as this to identify longer lasting, more tolerable treatments are urgently needed.

Overseen by a board of leading scientists, the Tres Cantos Open Lab Foundation provides funding and support to researchers to help them develop and advance new ideas that could lead to new medicines to treat diseases of the developing world. Researchers supported by the Foundation are encouraged to share their work to ensure their discoveries are also accessible to other researchers. www.openlabfoundation.org

Broader open innovation

The establishment of the Open Lab at Tres Cantos and the Tres Cantos Open Lab Foundation are among a number of open innovation measures implemented by GSK in recent years. GSK is a founding member of WIPO Re:Search - a collaboration of private and public sector organizations, which aims to accelerate the development of new and better treatments for neglected tropical diseases. Further moves made by GSK to share its intellectual property include the publication of all of its compounds that have shown activity against malaria (in 2010) and TB (in 2013) - a technique that has been proven to stimulate research - and its involvement in the "TB Drug Accelerator", which is another public / private partnership established with the specific aim of finding faster acting treatments for TB.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests. www.wellcome.ac.uk

GlaxoSmithKline Enquiries:

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502


David Daley

+44 (0) 20 8047 5502


Catherine Hartley

+44 (0) 20 8047 5502


US Media enquiries:

Stephen Rea

+1 215 751 4394


Kevin Colgan

+1 919 483 2933

(North Carolina)

Melinda Stubbee

+1 919 483 2510

(North Carolina)

Mary Anne Rhyne

+1 919 483 0492

(North Carolina)

Sarah Alspach

+1 202 715 1048

(Washington, DC)

Jennifer Armstrong

+1 215 751 5664


Analyst/Investor enquiries:

Ziba Shamsi

+ 44 (0) 20 8047 3289


Lucy Budd

+44 (0) 20 8047 2248


Tom Curry

+ 1 215 751 5419


Gary Davies

+ 44 (0) 20 8047 5503


James Dodwell

+ 44 (0) 20 8047 2406


Jeff McLaughlin

+ 1 215 751 7002


Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2012.

distributed by

© Publicnow 2013
02:12pGLAXOSMITHKLINE ( '') (FORM 6 K : GlaxoSmithKline plc (the 'Company') (Form 6-K)
11:21aEuropean ADRs Move Lower in Friday Trading
06:36aGLAXOSMITHKLINE : UBS sticks Neutral
02:10aGLAXOSMITHKLINE : Federal Circuit Vacates Judgment, Reinstates Jury's Verdict Of Induced I..
09/23GLOBAL MARKETS LIVE : Valneva,Boeing, Facebook, Kubota, Otis...
09/23Activist Bluebell Capital Takes Small Stake in GSK to Push for Board Change -FT
09/23GLAXOSMITHKLINE : Survey Shows More People In Favor Of Vaccinations After COVID-19
09/22GLAXOSMITHKLINE : CEO Faces Additional Pressure as Bluebell Joins Elliott in Demanding Man..
09/22GLAXOSMITHKLINE : Activist investor Bluebell takes stake in GSK to challenge chief exec
09/22Bluebell Capital Takes Stake in GlaxoSmithKline to Shake-up the Company’s Leadership
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Sales 2021 33 307 M 45 529 M 45 529 M
Net income 2021 3 857 M 5 272 M 5 272 M
Net Debt 2021 20 885 M 28 550 M 28 550 M
P/E ratio 2021 18,2x
Yield 2021 5,76%
Capitalization 69 468 M 94 962 M 94 962 M
EV / Sales 2021 2,71x
EV / Sales 2022 2,53x
Nbr of Employees 94 066
Free-Float 92,2%
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 1 388,00 GBX
Average target price 1 604,94 GBX
Spread / Average Target 15,6%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.44%433 991
ROCHE HOLDING AG10.87%324 441
PFIZER, INC.20.05%247 760
NOVO NORDISK A/S51.58%233 750